Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5155-5162

  Denève, Cécile ^a   Bouttier, Sylvie ^a   Dupuy, Bruno ^b   Barbut, Frédéric ^c   Collignon, Anne ^a,d   Janoir, Claire ^a  

^a University Paris Sud   (France)

^b INSTITUT PASTEUR   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d HÔPITAL JEAN VERDIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CLINDAMYCIN; FBP68 PROTEIN; FIBRONECTIN BINDING PROTEIN; HIGH MOLECULAR WEIGHT S LAYER PROTEIN; MOXIFLOXACIN; OFLOXACIN; PROTEASE CWP84; PROTEINASE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; VITRONECTIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE OVEREXPRESSION; IN VITRO STUDY; MOXIFLOXACIN RESISTANT CLOSTRIDIUM DIFFICILE; NONHUMAN; PRIORITY JOURNAL; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

AMPICILLIN; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIAL PROTEINS; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; CYSTEINE ENDOPEPTIDASES; DNA GYRASE; FRAMESHIFT MUTATION; IMMUNOBLOTTING; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; POLYMERASE CHAIN REACTION; QUINOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE DELETION;

EID: 71249128721     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00532-09     Document Type: Article

References (57)

1. Ackermann, G., Y. J. Tang, R. Kueper, P. Heisig, A. C. Rodloff, J. Silva, Jr., and S. H. Cohen. 2001. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob. Agents Chemother. 45:2348-2353. (Pubitemid 32664477)
2. Ackermann, G., Y. J. Tang-Feldman, R. Schaumann, J. P. Henderson, A. C. Rodloff, J. Silva, and S. H. Cohen. 2003. Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. Clin. Microbiol. Infect. 9:526-530.
3. Adams, D. A., M. M. Riggs, and C. J. Donskey. 2007. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob. Agents Chemother. 51:2674-2678.
4. Baines, S. D., J. Freeman, and M. H. Wilcox. 2005. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J. Antimicrob. Chemother. 55:974-982.
5. Biller, P., B. Shank, L. Lind, M. Brennan, L. Tkatch, G. Killgore, A. Thompson, and L. C. McDonald. 2007. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect. Control Hosp. Epidemiol. 28:198-201.
6. Bisognano, C., P. Vaudaux, P. Rohner, D. P. Lew, and D. C. Hooper. 2000. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob. Agents Chemother. 44:1428-1437.
7. Bisognano, C., P. E. Vaudaux, D. P. Lew, E. Y. Ng, and D. C. Hooper. 1997. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob. Agents Chemother. 41:906-913.
8. Calabi, E., F. Calabi, A. D. Phillips, and N. F. Fairweather. 2002. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect. Immun. 70:5770-5778.
9. Calabi, E., S. Ward, B. Wren, T. Paxton, M. Panico, H. Morris, A. Dell, G. Dougan, and N. Fairweather. 2001. Molecular characterization of the surface layer proteins from Clostridium difficile. Mol. Microbiol. 40:1187-1199.
10. Cerquetti, M., A. Molinari, A. Sebastianelli, M. Diociaiuti, R. Petruzzelli, C. Capo, and P. Mastrantonio. 2000. Characterization of surface layer proteins from different Clostridium difficile clinical isolates. Microb. Pathog. 28:363-372.
11. Cerquetti, M., A. Pantosti, P. Stefanelli, and P. Mastrantonio. 1992. Purification and characterization of an immunodominant 36 kDa antigen present on the cell surface of Clostridium difficile. Microb. Pathog. 13:271-279.
12. Cirz, R. T., M. B. Jones, N. A. Gingles, T. D. Minogue, B. Jarrahi, S. N. Peterson, and F. E. Romesberg. 2007. Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin. J. Bacteriol. 189: 531-539.
13. Davies, J., G. B. Spiegelman, and G. Yim. 2006. The world of subinhibitory antibiotic concentrations. Curr. Opin. Microbiol. 9:445-453.
14. Deneve, C., C. Delomenie, M. C. Barc, A. Collignon, and C. Janoir. 2008. Antibiotics involved in Clostridium difficile-associated disease increase colonization factor gene expression. J. Med. Microbiol. 57:732-738.
15. Deshpande, A., C. Pant, A. Jain, T. G. Fraser, and D. D. Rolston. 2008. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr. Med. Res. Opin. 24:329-333.
16. Dridi, L., J. Tankovic, B. Burghoffer, F. Barbut, and J. C. Petit. 2002. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob. Agents Chemother. 46: 3418-3421. (Pubitemid 35192906)
17. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
18. Drudy, D., E. Calabi, L. Kyne, S. Sougioultzis, E. Kelly, N. Fairweather, and C. P. Kelly. 2004. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol. Med. Microbiol. 41:237-242.
19. Drudy, D., L. Kyne, R. O'Mahony, and S. Fanning. 2007. gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg. Infect. Dis. 13:504-505.
20. Drudy, D., T. Quinn, R. O'Mahony, L. Kyne, P. O'Gaora, and S. Fanning. 2006. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J. Antimicrob. Chemother. 58:1264-1267. (Pubitemid 44884150)
21. Drummond, L. J., D. G. Smith, and I. R. Poxton. 2003. Effects of sub-MIC concentrations of antibiotics on growth of and toxin production by Clostridium difficile. J. Med. Microbiol. 52:1033-1038.
22. Emerson, J. E., R. A. Stabler, B. W. Wren, and N. F. Fairweather. 2008. Microarray analysis of the transcriptional responses of Clostridium difficile to environmental and antibiotic stress. J. Med. Microbiol. 57:757-764.
23. Freeman, J., F. J. O'Neill, and M. H. Wilcox. 2003. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J. Antimicrob. Chemother. 52:96-102.
24. Freeman, J., and M. H. Wilcox. 1999. Antibiotics and Clostridium difficile. Microbes Infect. 1:377-384.
25. Gerber, M., C. Walch, B. Loffler, K. Tischendorf, U. Reischl, and G. Ackermann. 2008. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile. J. Med. Microbiol. 57:776-783. (Pubitemid 351842072)
26. Goh, E. B., G. Yim, W. Tsui, J. McClure, M. G. Surette, and J. Davies. 2002. Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics. Proc. Natl. Acad. Sci. USA 99:17025-17030.
27. Hennequin, C., A. Collignon, and T. Karjalainen. 2001. Analysis of expression of GroEL (Hsp60) of Clostridium difficile in response to stress. Microb. Pathog. 31:255-260.
28. Hennequin, C., C. Janoir, M. C. Barc, A. Collignon, and T. Karjalainen. 2003. Identification and characterization of a fibronectin-binding protein from Clostridium difficile. Microbiology 149:2779-2787.
29. Herbert, S., P. Barry, and R. P. Novick. 2001. Subinhibitory clindamycin differentially inhibits transcription of exoprotein genes in Staphylococcus aureus. Infect. Immun. 69:2996-3003.
30. Honda, T., I. Hernadez, T. Katoh, and T. Miwatani. 1983. Stimulation of enterotoxin production of Clostridium difficile by antibiotics. Lancet 1:655.
31. Hooper, D. C. 1999. Mechanisms of fluoroquinolone resistance. Drug Resist. Updat. 2:38-55.
32. Janoir, C., S. Pechine, C. Grosdidier, and A. Collignon. 2007. Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins. J. Bacteriol. 189:7174-7180.
33. Johnson, S., M. H. Samore, K. A. Farrow, G. E. Killgore, F. C. Tenover, D. Lyras, J. I. Rood, P. DeGirolami, A. L. Baltch, M. E. Rafferty, S. M. Pear, and D. N. Gerding. 1999. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N. Engl. J. Med. 341:1645-1651.
34. Karjalainen, T., A. J. Waligora-Dupriet, M. Cerquetti, P. Spigaglia, A. Maggioni, P. Mauri, and P. Mastrantonio. 2001. Molecular and genomic analysis of genes encoding surface-anchored proteins from Clostridium difficile. Infect. Immun. 69:3442-3446.
35. Kuijper, E. J., B. Coignard, and P. Tull. 2006. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 12(Suppl. 6):2-18.
36. Lebel, S., S. Bouttier, and T. Lambert. 2004. The cme gene of Clostridium difficile confers multidrug resistance in Enterococcus faecalis. FEMS Microbiol. Lett. 238:93-100.
37. Loo, V. G., L. Poirier, M. A. Miller, M. Oughton, M. D. Libman, S. Michaud, A. M. Bourgault, T. Nguyen, C. Frenette, M. Kelly, A. Vibien, P. Brassard, S. Fenn, K. Dewar, T. J. Hudson, R. Horn, P. Rene, Y. Monczak, and A. Dascal. 2005. A predominantly clonal institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449.
38. MacCannell, D. R., T. J. Louie, D. B. Gregson, M. Laverdiere, A. C. Labbe, F. Laing, and S. Henwick. 2006. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from eastern and western Canada. J. Clin. Microbiol. 44:2147-2152.
39. Matamouros, S., P. England, and B. Dupuy. 2007. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol. Microbiol. 64: 1274-1288.
40. McDonald, L. C., G. E. Killgore, A. Thompson, R. C. Owens, Jr., S. V. Kazakova, S. P. Sambol, S. Johnson, and D. N. Gerding. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441.
41. Ohlsen, K., W. Ziebuhr, K. P. Koller, W. Hell, T. A. Wichelhaus, and J. Hacker. 1998. Effects of subinhibitory concentrations of antibiotics on alphatoxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 42:2817-2823. (Pubitemid 28501209)
42. Onderdonk, A. B., B. R. Lowe, and J. G. Bartlett. 1979. Effect of environmental stress on Clostridium difficile toxin levels during continuous cultivation. Appl. Environ. Microbiol. 38:637-641.
43. Pechine, S., A. Gleizes, C. Janoir, R. Gorges-Kergot, M. C. Barc, M. Delmee, and A. Collignon. 2005. Immunological properties of surface proteins of Clostridium difficile. J. Med. Microbiol. 54:193-196.
44. Pechine, S., C. Janoir, and A. Collignon. 2005. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J. Clin. Microbiol. 43:5018-5025.
45. Pepin, J., N. Saheb, M. A. Coulombe, M. E. Alary, M. P. Corriveau, S. Authier, M. Leblanc, G. Rivard, M. Bettez, V. Primeau, M. Nguyen, C. E. Jacob, and L. Lanthier. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41:1254-1260.
46. Pepin, J., L. Valiquette, and B. Cossette. 2005. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173:1037-1042.
47. Popoff, M. R., E. J. Rubin, D. M. Gill, and P. Boquet. 1988. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect. Immun. 56:2299-2306.
48. Pultz, N. J., and C. J. Donskey. 2005. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob. Agents Chemother. 49:3529-3532.
49. Sawai, J., T. Hasegawa, T. Kamimura, A. Okamoto, D. Ohmori, N. Nosaka, K. Yamada, K. Torii, and M. Ohta. 2007. Growth phase-dependent effect of clindamycin on production of exoproteins by Streptococcus pyogenes. Antimicrob. Agents Chemother. 51:461-467.
50. Spencer, R. C. 1998. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J. Antimicrob. Chemother. 41(Suppl. C):21-27.
51. Spigaglia, P., F. Barbanti, P. Mastrantonio, J. S. Brazier, F. Barbut, M. Delmee, E. Kuijper, and I. R. Poxton. 2008. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J. Med. Microbiol. 57:784-789.
52. Stabler, R. A., D. N. Gerding, J. G. Songer, D. Drudy, J. S. Brazier, H. T. Trinh, A. A. Witney, J. Hinds, and B. W. Wren. 2006. Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J. Bacteriol. 188:7297-7305.
53. Sullivan, A., C. Edlund, and C. E. Nord. 2001. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis. 1:101-114.
54. Tanaka, M., T. Hasegawa, A. Okamoto, K. Torii, and M. Ohta. 2005. Effect of antibiotics on group A Streptococcus exoprotein production analyzed by two-dimensional gel electrophoresis. Antimicrob. Agents Chemother. 49:88-96.
55. Walbrown, M. A., S. L. Aspinall, N. K. Bayliss, R. A. Stone, F. Cunningham, C. L. Squier, and C. B. Good. 2008. Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones. J. Manag. Care Pharm. 14:34-40.
56. Waligora, A. J., C. Hennequin, P. Mullany, P. Bourlioux, A. Collignon, and T. Karjalainen. 2001. Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Infect. Immun. 69:2144-2153.
57. Warny, M., J. Pepin, A. Fang, G. Killgore, A. Thompson, J. Brazier, E. Frost, and L. C. McDonald. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084.